Acer Therapeutics Inc. (DE) (ACER)
$0.66
$-0.14
(-17.95%)
As on 20-Nov-2023 16:00EDT
Market cap
$16 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
17.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-8 Mln
-
ROE
-4.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.9
-
Face value
--
-
Shares outstanding
24,463,700
10 Years Aggregate
CFO
$-147.64 Mln
EBITDA
$-172.27 Mln
Net Profit
$-181.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acer Therapeutics Inc. (DE) (ACER)
| -73.7 | -22.4 | -9.2 | -44.1 | -38.4 | -50.7 | -42.8 |
|
BSE Sensex*
| -10.9 | -4.9 | -8.9 | -7.6 | 6.9 | 8.3 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Acer Therapeutics Inc. (DE) (ACER)
| 10.1 | -13.0 | -34.7 | -80.1 | 45.0 | 45.4 | -66.8 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acer Therapeutics Inc. (DE) (ACER)
|
0.7 | 16.2 | 0.4 | -60.9 | -3,716.2 | -- | -- | 17.3 |
| 3.4 | 93.0 | 1.0 | -27.1 | -2,935.3 | -125.1 | -- | 6.0 | |
| 3.5 | 8.2 | 0.0 | -39.4 | -- | -54.6 | -- | 0.4 | |
| 228.7 | 43,154.8 | 2,300.4 | -750.2 | -35.0 | -28.5 | -- | 16.9 |
Shareholding Pattern
View DetailsAbout Acer Therapeutics Inc. (DE) (ACER)
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising... EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts. As of November 17, 2023, Acer Therapeutics Inc. operates as a subsidiary of Zevra Therapeutics, Inc. Read more
-
Founder, Pres, CEO & Director
Mr. Christopher Schelling
-
Founder, Pres, CEO & Director
Mr. Christopher Schelling
-
Headquarters
Newton, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Acer Therapeutics Inc. (DE) (ACER)
What is the current share price of Acer Therapeutics Inc (DE) (ACER) Today?
The share price of Acer Therapeutics Inc (DE) (ACER) is $0.66 (NASDAQ) as of 20-Nov-2023 16:00 EDT. Acer Therapeutics Inc (DE) (ACER) has given a return of -38.37% in the last 3 years.
What is the current PB & PE ratio of Acer Therapeutics Inc (DE) (ACER)?
Since, TTM earnings of Acer Therapeutics Inc (DE) (ACER) is negative, P/E ratio is not available.
The P/B ratio of Acer Therapeutics Inc (DE) (ACER) is 17.26 times as on 19-Dec-2023, a 323 premium to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.44
|
-2.40
|
|
2021
|
-2.17
|
-18.52
|
|
2020
|
-1.26
|
3.50
|
|
2019
|
-1.39
|
2.18
|
|
2018
|
-8.51
|
4.02
|
What is the 52 Week High and Low of Acer Therapeutics Inc (DE) (ACER)?
The 52-week high and low of Acer Therapeutics Inc (DE) (ACER) are Rs -- and Rs -- as of 23-May-2026.
What is the market cap of Acer Therapeutics Inc (DE) (ACER)?
Acer Therapeutics Inc (DE) (ACER) has a market capitalisation of $ 16 Mln as on 19-Dec-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Acer Therapeutics Inc (DE) (ACER)?
Before investing in Acer Therapeutics Inc (DE) (ACER), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.